Cardiac Resynchronization Therapy Reduces the Risk of Cardiac Events in Patients With Diabetes Enrolled in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)
Open Access
- 1 May 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 4 (3), 332-338
- https://doi.org/10.1161/circheartfailure.110.959510
Abstract
Background—: Data are limited regarding whether the presence of diabetes mellitus (DM) influences the benefit of cardiac resynchronization with defibrillator therapy (CRT-D) in heart failure (HF) patients. Methods and Results—: The effect of CRT-D was evaluated in 1817 patients who were enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Patients were minimally symptomatic (New York Heart Association class I or II), with ejection fraction ≤0.30 and QRS ≥130 ms. We used Cox regression to determine hazard ratio (HR) of CRT-D versus implantable cardioverter-defibrillator (ICD) therapy for the risk of HF event or death, whichever came first (MADIT-CRT primary end point), in DM (n=552) and non-DM (n=1265) patients. Compared with the non-DM patients, those with DM had more coronary risk factors. During an average follow-up of 2.4 years, DM patients had significantly more primary end point events than non-DM patients (26.6% versus 18%, P P P =0.003). Compared with non-DM patients, CRT-D:ICD HRs in DM patients were lower in the total population, and in subgroups with ischemic cardiomyopathy (0.63 versus 0.64), nonischemic cardiomyopathy (0.39 versus 0.73), and left bundle-branch block (0.36 versus 0.50). There were no significant differences in ventricular remodeling, arrhythmia events, or device-related complications between DM and non-DM patients. Conclusions—: Patients with diabetes, left ventricular dysfunction, mildly symptomatic HF, and wide QRS complex derive similar benefit from CRT-D compared with patients without diabetes. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00180271.Keywords
This publication has 27 references indexed in Scilit:
- Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure EventsNew England Journal of Medicine, 2009
- Diabetes, glucose level, and risk of sudden cardiac deathEuropean Heart Journal, 2005
- The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart FailureNew England Journal of Medicine, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart FailureNew England Journal of Medicine, 2004
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular ArrhythmiaNew England Journal of Medicine, 1996
- Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registryThe American Journal of Cardiology, 1996
- Criteria for intraventricular conduction disturbances and pre-excitationJournal of the American College of Cardiology, 1985
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974